Varinel

Varinel is a biotechnology company specializing in the development of advanced drug delivery systems designed to enhance the efficacy and safety of oncology therapeutics. The company's core technology focuses on the targeted delivery of established chemotherapeutic agents to increase their concentration within solid tumors while reducing systemic exposure and toxicity. Varinel's lead candidate, V-101, is a proprietary formulation of docetaxel aimed at treating various solid tumors. Founded in 2011 and based in Pennsylvania, the company leverages its platform to address unmet needs in cancer and infectious disease treatment. In 2021, Varinel was acquired by Auctus Therapeutics to further advance its delivery technology and clinical pipeline.